Bio-Rad Laboratories, Inc. (BIO.B) stock
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Bio-Rad Laboratories r&d expenses
Research and development expenses are spending on new products and technology.
Bio-Rad Laboratories's R&D Expenses for the twelve months ending Jun 30, 2026 was $265.70M, down 12.8% year over year. For fiscal 2025 it was $275.60M, down 6.9% from the year before. Over ten years it grew 3.6% a year on average. The highest annual figure on record is $295.90M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $275.60M | -6.9% |
| FY2024 | Dec 31, 2024 | $295.90M | +19.6% |
| FY2023 | Dec 31, 2023 | $247.40M | -3.7% |
| FY2022 | Dec 31, 2022 | $256.90M | -1.4% |
| FY2021 | Dec 31, 2021 | $260.64M | +19.7% |
| FY2020 | Dec 31, 2020 | $217.76M | +7.4% |
| FY2019 | Dec 31, 2019 | $202.71M | +1.8% |
| FY2018 | Dec 31, 2018 | $199.20M | -20.4% |
| FY2017 | Dec 31, 2017 | $250.16M | +21.6% |
| FY2016 | Dec 31, 2016 | $205.71M | +6.6% |
| FY2015 | Dec 31, 2015 | $192.97M | -12.4% |
| FY2014 | Dec 31, 2014 | $220.33M | +4.4% |
| FY2013 | Dec 31, 2013 | $210.95M | +0.8% |
| FY2012 | Dec 31, 2012 | $209.20M | +17.8% |
| FY2011 | Dec 31, 2011 | $177.60M | +3.1% |
| FY2010 | Dec 31, 2010 | $172.27M | +5.3% |
| FY2009 | Dec 31, 2009 | $163.59M | +2.5% |
| FY2008 | Dec 31, 2008 | $159.52M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $61.20M | +1.2% |
| Q1 FY2026 | Mar 31, 2026 | $62.90M | -14.4% |
| Q4 FY2025 | Dec 31, 2025 | $70.30M | -11.7% |
| Q3 FY2025 | Sep 30, 2025 | $71.30M | -21.6% |
| Q2 FY2025 | Jun 30, 2025 | $60.50M | +2.7% |
| Q1 FY2025 | Mar 31, 2025 | $73.50M | +10.7% |
| Q4 FY2024 | Dec 31, 2024 | $79.60M | +24.6% |
| Q3 FY2024 | Sep 30, 2024 | $91.00M | +109.0% |
| Q2 FY2024 | Jun 30, 2024 | $58.90M | -9.4% |
| Q1 FY2024 | Mar 31, 2024 | $66.40M | -11.4% |
| Q4 FY2023 | Dec 31, 2023 | $63.87M | -3.5% |
| Q3 FY2023 | Sep 30, 2023 | $43.54M | -34.8% |
| Q2 FY2023 | Jun 30, 2023 | $65.04M | +1.1% |
| Q1 FY2023 | Mar 31, 2023 | $74.95M | +25.9% |
| Q4 FY2022 | Dec 31, 2022 | $66.21M | +12.5% |
| Q3 FY2022 | Sep 30, 2022 | $66.81M | +3.6% |
| Q2 FY2022 | Jun 30, 2022 | $64.35M | +1.5% |
| Q1 FY2022 | Mar 31, 2022 | $59.54M | -19.5% |
| Q4 FY2021 | Dec 31, 2021 | $58.85M | +3.4% |
| Q3 FY2021 | Sep 30, 2021 | $64.48M | +8.3% |
| Q2 FY2021 | Jun 30, 2021 | $63.39M | +21.9% |
| Q1 FY2021 | Mar 31, 2021 | $73.91M | +49.9% |
| Q4 FY2020 | Dec 31, 2020 | $56.93M | -0.2% |
| Q3 FY2020 | Sep 30, 2020 | $59.55M | +24.2% |
| Q2 FY2020 | Jun 30, 2020 | $51.98M | +3.7% |
| Q1 FY2020 | Mar 31, 2020 | $49.30M | +3.6% |
| Q4 FY2019 | Dec 31, 2019 | $57.07M | +7.5% |
| Q3 FY2019 | Sep 30, 2019 | $47.94M | -2.6% |
| Q2 FY2019 | Jun 30, 2019 | $50.12M | +5.6% |
| Q1 FY2019 | Mar 31, 2019 | $47.58M | -3.7% |
| Q4 FY2018 | Dec 31, 2018 | $53.07M | -30.3% |
| Q3 FY2018 | Sep 30, 2018 | $49.25M | -20.7% |
| Q2 FY2018 | Jun 30, 2018 | $47.45M | -24.2% |
| Q1 FY2018 | Mar 31, 2018 | $49.43M | -0.1% |
| Q4 FY2017 | Dec 31, 2017 | $76.10M | +32.1% |
| Q3 FY2017 | Sep 30, 2017 | $62.08M | +24.4% |
| Q2 FY2017 | Jun 30, 2017 | $62.59M | – |
| Q1 FY2017 | Mar 31, 2017 | $49.45M | – |
| Q4 FY2016 | Dec 31, 2016 | $57.60M | – |
| Q3 FY2016 | Sep 30, 2016 | $49.90M | – |